HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients

• Published in: PloS one Vol. 12; no. 12; p. e0187409
• Main Authors: Canini, Laetitia, Imamura, Michio, Kawakami, Yoshiiku, Uprichard, Susan L., Cotler, Scott J., Dahari, Harel, Chayama, Kazuaki
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 07.12.2017; Public Library of Science (PLoS)
• Subjects: Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Biology and life sciences; Complications and side effects; Daclatasvir; Dosage and administration; Drug therapy; Hepacivirus - physiology; Hepatitis C; Hepatitis C, Chronic - drug therapy; Humans; Imidazoles - administration & dosage; Imidazoles - therapeutic use; Isoquinolines - administration & dosage; Isoquinolines - therapeutic use; Kinetics; Life Sciences; Medicine and health sciences; Research and Analysis Methods; Sulfonamides - administration & dosage; Sulfonamides - therapeutic use; United States; United Kingdom

High cure rates are achieved in HCV genotype-1b patients treated with daclatasvir and asunaprevir, DCV/ASV. Here we analyzed early HCV kinetics in genotype-1b infected Japanese subjects treated with DCV/ASV and retrospectively projected, using mathematical modeling, whether shorter treatment duratio...